Explore
Validate
Learn10818-1-AP
antibody from Proteintech Group
Targeting: ERCC2
EM9, MAG, MGC102762, MGC126218, MGC126219, XPD
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations
- Western blot [1]
- Immunoprecipitation [1]
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 10818-1-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#10818-1-AP, RRID:AB_2231330
- Product name
- ERCC2 antibody
- Antibody type
- Polyclonal
- Description
- ERCC2 antibody (Cat. #10818-1-AP) is a rabbit polyclonal antibody that shows reactivity with human and has been validated for the following applications: IHC, IP, WB, ELISA.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references Predictive value of ERCC1, ERCC2, ERCC4, and glutathione S-Transferase Pi expression for the efficacy and safety of FOLFIRINOX in patients with unresectable pancreatic cancer.
MiR-770-5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting ERCC2.
Synchronous detection of miRNAs, their targets and downstream proteins in transferred FFPE sections: applications in clinical and basic research.
Very low prevalence of XPD K751Q polymorphism and its association with XPD expression and outcomes of FOLFOX-4 treatment in Asian patients with colorectal carcinoma.
Tezuka S, Ueno M, Kobayashi S, Morimoto M, Ohkawa S, Hirotani A, Tozuka Y, Moriya S, Nakamura Y, Miyagi Y, Sugimori M, Maeda S
American journal of cancer research 2018;8(10):2096-2105
American journal of cancer research 2018;8(10):2096-2105
MiR-770-5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting ERCC2.
Zhao H, Yu X, Ding Y, Zhao J, Wang G, Wu X, Jiang J, Peng C, Guo GZ, Cui S
Oncotarget 2016 Aug 16;7(33):53254-53268
Oncotarget 2016 Aug 16;7(33):53254-53268
Synchronous detection of miRNAs, their targets and downstream proteins in transferred FFPE sections: applications in clinical and basic research.
Zhao JY, Liu CQ, Zhao HN, Ding YF, Bi T, Wang B, Lin XC, Guo G, Cui SY
Methods (San Diego, Calif.) 2012 Oct;58(2):156-63
Methods (San Diego, Calif.) 2012 Oct;58(2):156-63
Very low prevalence of XPD K751Q polymorphism and its association with XPD expression and outcomes of FOLFOX-4 treatment in Asian patients with colorectal carcinoma.
Lai JI, Tzeng CH, Chen PM, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS, Wang WS
Cancer science 2009 Jul;100(7):1261-6
Cancer science 2009 Jul;100(7):1261-6
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- HeLa cells were subjected to SDS PAGE followed by western blot with 10818-1-AP(ERCC2 antibody) at dilution of 1:500
- Sample type
- cell line
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- IP Result of anti-ERCC2 (IP:10818-1-AP, 5ug; Detection:10818-1-AP 1:500) with K-562 cells lysate 8000ug.
- Sample type
- cell line
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The ERCC2 antibody from Proteintech is a rabbit polyclonal antibody to a recombinant protein of human ERCC2. This antibody recognizes human antigen. The ERCC2 antibody has been validated for the following applications: ELISA, WB, IHC, IP analysis.
